Antineoplastics
1
Reactions 1495, p8 - 5 Apr 2014 Antineoplastics Stomatitis and mucositis in an elderly patient: case report A 67-year-old man developed stomatitis while receiving fluorouracil, folinic acid [leucovorin] and oxaliplatin (FOLFOX) for metastatic colorectal cancer. He then developed mucositis during treatment with cetuximab [routes, durations of treatment to reactions onset and outcomes not stated; not all dosages stated]. The man, who had been diagnosed with colorectal cancer in 2008, was diagnosed with metastatic disease in April 2011. He began receiving FOLFOX, consisting of a fluorouracil 200 mg/m 2 bolus and 1200 mg/m 2 continuous infusion over 48h, folinic acid and oxaliplatin 75 mg/m 2 every 2 weeks. During treatment, he developed grade 2 stomatitis. After receiving a total of 21 cycles of FOLFOX, he was switched to cetuximab. He received a 400 mg/m 2 loading dose followed by 250 mg/m 2 weekly. He subsequently developed grade 2 mucositis. At last follow-up, he continued to receive cetuximab. Author comment: "The patient tolerated his [FOLFOX] treatment very well, with only grade 2 stomatitis as a significant toxicity. . . He tolerated this [cetuximab] treatment very well, with only grade 2 mucositis." Elsoueidi R, et al. Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction. Journal of the National Comprehensive Cancer Network 12: 155-160, No. 2, Feb 2014 - USA 803101133 1 Reactions 5 Apr 2014 No. 1495 0114-9954/14/1495-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
-
Upload
duongkhuong -
Category
Documents
-
view
213 -
download
0
Transcript of Antineoplastics
Reactions 1495, p8 - 5 Apr 2014
Antineoplastics
Stomatitis and mucositis in an elderly patient: casereport
A 67-year-old man developed stomatitis while receivingfluorouracil, folinic acid [leucovorin] and oxaliplatin (FOLFOX)for metastatic colorectal cancer. He then developed mucositisduring treatment with cetuximab [routes, durations oftreatment to reactions onset and outcomes not stated; not alldosages stated].
The man, who had been diagnosed with colorectal cancer in2008, was diagnosed with metastatic disease in April 2011. Hebegan receiving FOLFOX, consisting of a fluorouracil200 mg/m2 bolus and 1200 mg/m2 continuous infusion over48h, folinic acid and oxaliplatin 75 mg/m2 every 2 weeks.During treatment, he developed grade 2 stomatitis. Afterreceiving a total of 21 cycles of FOLFOX, he was switched tocetuximab. He received a 400 mg/m2 loading dose followed by250 mg/m2 weekly. He subsequently developed grade 2mucositis. At last follow-up, he continued to receivecetuximab.
Author comment: "The patient tolerated his [FOLFOX]treatment very well, with only grade 2 stomatitis as asignificant toxicity. . . He tolerated this [cetuximab] treatmentvery well, with only grade 2 mucositis."Elsoueidi R, et al. Safety and efficacy of FOLFOX followed by cetuximab formetastatic colorectal cancer with severe liver dysfunction. Journal of the NationalComprehensive Cancer Network 12: 155-160, No. 2, Feb 2014 - USA 803101133
1
Reactions 5 Apr 2014 No. 14950114-9954/14/1495-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved
